1. Home
  2. CVEO vs CINGW Comparison

CVEO vs CINGW Comparison

Compare CVEO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVEO
  • CINGW
  • Stock Information
  • Founded
  • CVEO 1977
  • CINGW N/A
  • Country
  • CVEO United States
  • CINGW United States
  • Employees
  • CVEO N/A
  • CINGW 13
  • Industry
  • CVEO Hotels/Resorts
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CVEO Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • CVEO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • CVEO N/A
  • CINGW N/A
  • IPO Year
  • CVEO N/A
  • CINGW 2021
  • Fundamental
  • Price
  • CVEO $23.72
  • CINGW $0.08
  • Analyst Decision
  • CVEO Strong Buy
  • CINGW
  • Analyst Count
  • CVEO 1
  • CINGW 0
  • Target Price
  • CVEO $32.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • CVEO 49.3K
  • CINGW N/A
  • Earning Date
  • CVEO 02-27-2025
  • CINGW N/A
  • Dividend Yield
  • CVEO 4.22%
  • CINGW N/A
  • EPS Growth
  • CVEO N/A
  • CINGW N/A
  • EPS
  • CVEO 1.44
  • CINGW N/A
  • Revenue
  • CVEO $701,970,000.00
  • CINGW N/A
  • Revenue This Year
  • CVEO $0.97
  • CINGW N/A
  • Revenue Next Year
  • CVEO $3.72
  • CINGW N/A
  • P/E Ratio
  • CVEO $16.42
  • CINGW N/A
  • Revenue Growth
  • CVEO 1.41
  • CINGW N/A
  • 52 Week Low
  • CVEO $21.15
  • CINGW N/A
  • 52 Week High
  • CVEO $28.92
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CVEO 55.77
  • CINGW N/A
  • Support Level
  • CVEO $23.50
  • CINGW N/A
  • Resistance Level
  • CVEO $24.13
  • CINGW N/A
  • Average True Range (ATR)
  • CVEO 0.46
  • CINGW 0.00
  • MACD
  • CVEO 0.22
  • CINGW 0.00
  • Stochastic Oscillator
  • CVEO 81.02
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: